title: The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
abstract: BACKGROUND
  The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients.
  
  
  METHODS
  The EORTC trial 10951 randomised 122 postmenopausal breast cancer patients to exemestane (E) 25 mg (n = 62) or tamoxifen (T) 20 mg (n = 60) once daily as a first-line treatment in the metastatic setting. Exemestane showed promising results in all the primary efficacy end points of the trial (response rate, clinical benefit rate and response duration), and it was well tolerated with low incidence of serious toxicity. As a secondary end point of this phase II trial, serum triglycerides (TRG), high-density lipoprotein cholesterol (HDL), total cholesterol (TC), lipoprotein a (Lip a), and apolipoproteins (Apo) B and A1 were measured at baseline and while on therapy (at 8, 24 and 48 weeks) to assess the impact of exemestane and tamoxifen on serum lipid profiles. Of the 122 randomised patients, those who had baseline and at least one other lipid assessment are included in the present analysis. The patients who received concomitant drugs that could affect lipid profile are included only if these drugs were administered throughout the study treatment. Increase or decrease in lipid parameters within 20% of baseline were considered as non-significant and thus unchanged.
  
  
  RESULTS
  Seventy-two patients (36 in both arms) were included in the statistical analysis. The majority of patients had abnormal TC and normal TRG, HDL, Apo A1, Apo B and Lip a levels at baseline. Neither exemestane nor tamoxifen had adverse effects on TC, HDL, Apo A1, Apo B or Lip a levels at 8, 24 and 48 weeks of treatment. Exemestane and tamoxifen had opposite effects on TRG levels: exemestane lowered while tamoxifen increased TRG levels over time. There were too few patients with normal baseline TC and abnormal TRG, HDL, Apo A1, Apo B and Lip a levels to allow for assessment of E's impact on these subsets. The atherogenic risk determined by Apo A1:Apo B and TC:HDL ratios remained unchanged throughout the treatment period in both the E and T arms.
  
  
  CONCLUSIONS
  Overall, exemestane has no detrimental effect on cholesterol levels and the atherogenic indices, which are well-known risk factors for coronary artery disease. In addition, it has a beneficial effect on TRG levels. These data, coupled with E's excellent efficacy and tolerability, support further exploration of its potential in the metastatic, adjuvant and chemopreventive setting.
authors.affiliation: Jules Bordet Institute, Brussels, Belgium.
authors.forename: G
authors.initials: G
authors.lastname: Atalay
authors.forename: L
authors.initials: L
authors.lastname: Dirix
authors.forename: L
authors.initials: L
authors.lastname: Biganzoli
authors.forename: L
authors.initials: L
authors.lastname: Beex
authors.forename: M
authors.initials: M
authors.lastname: Nooij
authors.forename: D
authors.initials: D
authors.lastname: Cameron
authors.forename: C
authors.initials: C
authors.lastname: Lohrisch
authors.forename: T
authors.initials: T
authors.lastname: Cufer
authors.forename: J P
authors.initials: JP
authors.lastname: Lobelle
authors.forename: M R
authors.initials: MR
authors.lastname: Mattiaci
authors.forename: M
authors.initials: M
authors.lastname: Piccart
authors.forename: R
authors.initials: R
authors.lastname: Paridaens
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000730:Androstadienes / Q000494:pharmacology* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002784:Cholesterol / Q000097:blood*; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017698:Postmenopause; D012307:Risk Factors; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D008055:Lipids; D013629:Tamoxifen; D002784:Cholesterol; C056516:exemestane